骨髓增生异常综合征的治疗：阿扎胞苷治疗经验引发的问题 - Suppr

Suppr

超能文献

Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience.

作者信息

Kantarjian Hagop M

出版信息

J Clin Oncol. 2002 May 15;20(10):2415-6. doi: 10.1200/JCO.2002.20.10.2415.

DOI:10.1200/JCO.2002.20.10.2415

PMID:12011118

Abstract

摘要

相似文献

Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience.

J Clin Oncol. 2002 May 15;20(10):2415-6. doi: 10.1200/JCO.2002.20.10.2415.

Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile.

Am J Hematol. 2014 May;89(5):565. doi: 10.1002/ajh.23677. Epub 2014 Feb 28.

Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.

Leuk Res. 2009 Dec;33 Suppl 2:S7-11. doi: 10.1016/S0145-2126(09)70227-9.

The euphoria of hypomethylating agents in MDS and AML: is it justified?

Best Pract Res Clin Haematol. 2013 Sep;26(3):275-8. doi: 10.1016/j.beha.2013.10.001. Epub 2013 Oct 15.

Azacitidine and the beginnings of therapeutic epigenetic modulation.

Expert Opin Pharmacother. 2008 Aug;9(11):1981-6. doi: 10.1517/14656566.9.11.1981.

Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis.

Haematologica. 2010 Feb;95(2):340-2; author reply 343-4. doi: 10.3324/haematol.2009.017764. Epub 2009 Oct 22.

Decitabine in myelodysplastic syndromes: viewpoints.

Drugs. 2006;66(7):959-60. doi: 10.2165/00003495-200666070-00013.

5'-azacitidine in myelodysplastic syndromes with inversion of chromosome 3.

Leukemia. 2011 Apr;25(4):736-7. doi: 10.1038/leu.2011.6. Epub 2011 Feb 4.

Azacitidine.

Nat Rev Drug Discov. 2005 May;Suppl:S6-7. doi: 10.1038/nrd1726.

Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.

Eur J Haematol. 2011 Aug;87(2):186-8. doi: 10.1111/j.1600-0609.2011.01653.x.

引用本文的文献

Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes.

Cancer Res. 2020 Sep 15;80(18):3775-3785. doi: 10.1158/0008-5472.CAN-19-3837. Epub 2020 May 7.

Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.

Gynecol Oncol. 2010 Feb;116(2):195-201. doi: 10.1016/j.ygyno.2009.09.043. Epub 2009 Oct 24.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience.

J Clin Oncol. 2002 May 15;20(10):2415-6. doi: 10.1200/JCO.2002.20.10.2415.

Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile.

Am J Hematol. 2014 May;89(5):565. doi: 10.1002/ajh.23677. Epub 2014 Feb 28.

Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.

Leuk Res. 2009 Dec;33 Suppl 2:S7-11. doi: 10.1016/S0145-2126(09)70227-9.

The euphoria of hypomethylating agents in MDS and AML: is it justified?

Best Pract Res Clin Haematol. 2013 Sep;26(3):275-8. doi: 10.1016/j.beha.2013.10.001. Epub 2013 Oct 15.

Azacitidine and the beginnings of therapeutic epigenetic modulation.

Expert Opin Pharmacother. 2008 Aug;9(11):1981-6. doi: 10.1517/14656566.9.11.1981.

Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis.

Haematologica. 2010 Feb;95(2):340-2; author reply 343-4. doi: 10.3324/haematol.2009.017764. Epub 2009 Oct 22.

Decitabine in myelodysplastic syndromes: viewpoints.

Drugs. 2006;66(7):959-60. doi: 10.2165/00003495-200666070-00013.

5'-azacitidine in myelodysplastic syndromes with inversion of chromosome 3.

Leukemia. 2011 Apr;25(4):736-7. doi: 10.1038/leu.2011.6. Epub 2011 Feb 4.

Azacitidine.

Nat Rev Drug Discov. 2005 May;Suppl:S6-7. doi: 10.1038/nrd1726.

Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.

Eur J Haematol. 2011 Aug;87(2):186-8. doi: 10.1111/j.1600-0609.2011.01653.x.

引用本文的文献

Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes.

Cancer Res. 2020 Sep 15;80(18):3775-3785. doi: 10.1158/0008-5472.CAN-19-3837. Epub 2020 May 7.

Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.

Gynecol Oncol. 2010 Feb;116(2):195-201. doi: 10.1016/j.ygyno.2009.09.043. Epub 2009 Oct 24.